Vaccine delivery carriers: Insights and future perspectives

Correia‐Pinto, Jorge; Csaba, Nœmi; Alonso, Marı́a José

doi:10.1016/j.ijpharm.2012.04.047

Cited by 107 publications

(62 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3) [67], following intramuscular administration. In contrast to the unmodified chitosan nanoparticles, which show high immunogenicity after oral administration, TMC nanoparticles displayed a high adjuvant effect after intramuscular injection [68]. ity to o the atory environment that cause the activation of the immune system [71].…”

Section: Polysaccharide and Polyanhydride-based Nanocarriersmentioning

confidence: 98%

Revolutionary impact of nanovaccines on immunotherapy

Shahbazi

Santos

2014

European Journal of Molecular &Amp; Clinical Medicine

View full text Add to dashboard Cite

Over the past few decades, public health has been immensely improved by preventing various types of diseases using vaccination, a method implying attenuated, killed or part of a microorganism to activate the immune system against it. Recently, nanovaccines have attracted a lot of attention as a new approach for enhancing the immune responses against immunogenic molecules. A wide variety 2 of nanomaterials are reported as proper candidates for nano-vaccination. Currently, the focus of nanovaccines researches are developing new formulations that trigger strong anti-cancer responses by presenting tumor antigens either directly to T immune cells or indirectly to antigen-presenting cells, holding great promise for safe, non-invasive, and cost-effective therapy of cancer. This review focuses on the critical aspects in the design of biomaterial based nanovaccines and reviews the state of the art of the formulations in clinical development and those currently marketed. Focal points:• BedsideUnderstanding the complex potential of the immune system to prevent and treat various diseases such as cancer, will contribute to the scientific advance in the development of new therapeutic strategies and will allow for the discovery of alternative treatments for deadly diseases. • BenchsideMany of the immunostimulative pathways involved in the suppression of cancer tumor growth have been identified and additional research is still needed to recognize the molecular mechanisms of the immunotherapeutic strategies. • IndustryThe discovery of new non-toxic immunotherapeutic compounds may pave the way towards developing new cancer tumor therapeutic approaches. A major effort in the identification of preventing approaches is also needed to develop preventive nanoformulations for healthy people who are at the risk of cancer. • CommunityThe treatment of cancer by cheap, efficient and as less invasive as possible methodologies will have a great impact on the quality of life of the patients. • GovernmentsSince the development of anticancer nanoformulations needs extensive support from the authorities for success in clinical translation, the financial investments of the governments is necessary to translate the research in the lab to the bedside. The governmental support can also increase the years of healthy life of the patients and minimize the associated costs overtime.

show abstract

Section: Polysaccharide and Polyanhydride-based Nanocarriersmentioning

confidence: 98%

Revolutionary impact of nanovaccines on immunotherapy

Shahbazi

Santos

2014

European Journal of Molecular &Amp; Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…Following subcutaneous, intradermal or intramuscular administration, the majority of small NPs (< 20 nm) will preferably drain to blood capillaries and subsequently be eliminated by the organism; NPs between 20 and 100 nm will penetrate the extracellular matrix, enter directly into the lymphatic vessels, travel to the lymphatic nodes where they will be taken up by immune cells, in particular DCs; larger NPs (> 100 nm) will most likely stay at the injection sites until they are captured by peripheral DC and then migrate to lymphatic nodes to initiate immune response. 54 However, due to their physical characteristics, NPs can also be internalized by scavenger cells, such as Mf, which have impaired T cell priming capacity compared to DC. Kim et al showed that, at least with NPs composed of poly-g-glutamic acid and L-phenylalanine ethyl ester, small NPs having diameter in a range of approximately 30-130 nm were less accumulated into DCs in vitro, compared with larger NPs having diameter in range of 190-360 nm, although DC activation was strong with both types.…”

Section: Influence Of Biophysical Features Of Nps On Tumor Targetingmentioning

confidence: 99%

Potential applications of nanoparticles in cancer immunotherapy

Jia

Omri

Krishnan

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In recent years considerable progress has been made in the field of cancer immunotherapy whereby treatments that modulate the body's own immune system are used to combat cancer. This has the potential to not only elicit strong anti-cancer immune responses which can break pre-existing tolerance and help promote tumor regression, but could also induce immunological memory which may help prevent tumor recurrence. In order to ensure effective delivery of immunotherapeutic agents, such as vaccines, checkpoint inhibitors, chemotherapeutic agents and nucleic acids, a safe and effective delivery system is often required. One such approach is the use of multifunctional nanoparticles (NPs), such as liposomes, polymers, micelles, dendrimers, inorganic NPs, and hybrid NPs, which have the potential to combine the delivery of a diverse range of therapeutic immunomodulators thereby increasing the efficacy of tumor cell killing. This review focuses on recent progress in NP-mediated immunotherapy for the treatment of cancer.

show abstract

“…DNA-based vaccines to provide full immunity against many antigens (23)(24)(25). Compared with lifelong administration required for most proposed cancer prevention agents, a short series of vaccinations is much more feasible, especially in at-risk populations that are difficult to reach.…”

Section: Ease Of Delivery and Cost Effectivenessmentioning

confidence: 99%

Cancer Immunoprevention: A New Approach to Intercept Cancer Early

Umar

2014

Cancer Prevention Research

View full text Add to dashboard Cite

Cancer immunoprevention refers to the modulation of the host immune response to control the initiation or development of cancer. The significant role of host immunity in early tumorigenesis has only recently been confirmed, as a better understanding of the mechanisms, molecules and cells involved in tumor immunology have been elucidated over the past two decades. Of utmost importance, preclinical and clinical evidences have demonstrated that early neoplastic cells (transformed cells that initiate cancer formation) express antigens that allow the immune system to distinguish them from normal cells. Furthermore, recognition of the aberrant cell by the immune cells activates a complex interaction of mutual modulation between the immune cells, the tumor and the tumor microenvironment that may result not only in inhibition but also promotion of cancer. The deepening understanding of cancer-related immunologic processes, properties, and components has spawned exploration of more rational, mechanism-based immunologic strategies (using vaccines, antibodies, and immune modulators) for cancer prevention. This introduction to the Cancer Prevention Research immunoprevention series will attempt to review the basics of the immune response modulation as a basis for potential application to cancer immunoprevention strategies with an emphasis on vaccines. Recognizing the fast-paced research in immune response modulation, the series will cover current understandings and future directions of cancer immunoprevention research. See all articles in this Cancer Prevention Research collection, "Cancer Immunoprevention Series." Cancer Prev Res; 7(11); 1067-71. Ó2014 AACR. Mechanistic Bases of Immunoprevention: A Primer Innate versus adaptive immunityThe concept of cancer immunomodulation is based on the physiologic immune response during the natural course of disease (1-3). The immune response has been historically divided into two types: innate and adaptive (4, 5). The innate immune response provides immediate, short-term protection against a variety of nonspecific antigens. In contrast, adaptive immune responses develop over a longer period of time, are specific, and provide long-term protection. Activation of innate and subsequent adaptive immunity is fundamental to effective immunologic eradication of exogenous and endogenous pathogens and undesirable endogenous cells (e.g., cancer cells).The essential components of each type of immunity differ, but their activities overlap. The elements of the innate immune system are (i) epithelial barriers, (ii) phagocytic leukocytes, (iii) dendritic cells (DC), (iv) natural killer (NK) cells, and (v) circulating plasma proteins. Elements of the adaptive immune system fall into two functional categories: humoral immunity, mediated by the antibodies produced by B lymphocytes, and cellular immunity, mediated by T lymphocytes (6). DCs are one of the major sentinels of both innate and adaptive immune responses.During the innate response, DCs scan for potential pathogens using Toll-like recepto...

show abstract

Vaccine delivery carriers: Insights and future perspectives

Cited by 107 publications

References 149 publications

Revolutionary impact of nanovaccines on immunotherapy

Revolutionary impact of nanovaccines on immunotherapy

Potential applications of nanoparticles in cancer immunotherapy

Cancer Immunoprevention: A New Approach to Intercept Cancer Early

Contact Info

Product

Resources

About